The Oncology Biosimilars market study analyzes each market player encompassed in the market study as per its market share, production footprint, current launches, agreements, ongoing R&D projects, and market strategies. SWOT analysis has been performed in the market study to investigate the strengths, weaknesses, opportunities and threats of each player.

To remain ‘ahead’ of your competitors, request for a sample –

The blood cancers segment is projected to expand the fastest, at a whopping 33.0% CAGR during the forecast period. This is mostly attributed to a rising number of novel drugs in the pipeline of key manufacturers. The blood cancers segment is anticipated to capture more than 1/5th of the total oncology biosimilars market.

However, the neutropenia segment is poised to dominate the global oncological biosimilars market, capturing more than half of the total market share. Expiration of patented blockbuster biologics has paved way for increased usage of biosimilar products in the segment. In 2018, the FDA approved the use of filgrastim-aafi manufactured by Pfizer, for treating neutropenia among patients who have undergone blood cancer treatment. The neutropenia segment is anticipated to expand at a dexterous CAGR of 29.6%.

For critical insights on this market, request for methodology here –

global oncolology biosimilars market size growth forecast by disease indication

Global Oncology Biosimilars Market Regional Insights:

The Asia-Pacific oncology biosimilars market is set to register aggrandizing growth, expanding at a CAGR of 30.7%, thus reaching a position of market dominance. The Asia-Pacific market is poised to capture more than one-third of the overall market. This impressive growth trajectory is attributed to active collaboration within market giants to expand profit pools. For instance, in 2016, Dr. Reddy’s Laboratories collaborated with TR-Pharm to commercialize the former’s three biosimilars in Turkey.

Read More Trending Reports of Fact.MR-

Global Oncology biosimilars Market Segmentation

Fact.MR has studied the global oncology biosimilars market with detailed segmentation on the basis of drug class, disease indication, distribution channel and region.

Drug Class

Disease Indication

Distribution Channel


G-CSF Breast Cancer Hospital Pharmacy North America
Monoclonal Antibody Non-Small Cell Lung Cancer Retail Pharmacy Europe
Hematopoietic Agents Colorectal Cancer Online Pharmacy Asia Pacific
  Neutropenia   Rest of the World
  Blood Cancer:


Myeloid Leukemia

Chronic Lymphocytic Leukemia (CLL)



Non-Hodgkin Lymphoma



The Oncology Biosimilars market report provides the readers with the below-mentioned insights:

  • Key trends, including ecological conservation, patented solutions, and globalization.
  • Consumption pattern of each segment of the market in every region.
  • Detailed study of the factors (positive and negative) impacting the growth of the global Endobronchial Valves market.
  • Critical analysis of R&D activities performed by market players to expand their production footprint across various industries.
  • Thorough research of effect of the market across various end use industries.

To connect an Expert –

The Oncology Biosimilars market report gets rid of the following queries:

  1. Which end use has the highest rate of consumption and why?
  2. Which regions are the market players targeting to gain a competitive edge?
  3. What is the growth forecast of the global market in region?
  4. What is the Y-o-Y growth rate of the global market?
  5. Which segment will have the maximum share of the global market by the end of year?

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

Prepackaged Medical Kits and Trays Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2022 to 2030:

Cables and Leads for Medical Equipment Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2022 to 2030:

Coatings for Medical Devices Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2022 to 2030:

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office:

11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: [email protected]
Visit Our Website: